Conference Coverage

A refined strategy for confirming diagnosis in suspected NSTEMI


 

REPORTING FROM ACC 18


“I totally agree with you,” Dr. Smulders replied. “We need a bigger trial to confirm our results – preferably a multicenter trial.”

“How can you do a bigger trial when your data safety monitoring board didn’t allow you to complete even this trial? They killed your trial. That’s the way I see it,” Dr. Anker said.

The CARMENTA trial was funded by the Dutch Heart Foundation. Dr. Smulders reported having no financial conflicts of interest.

SOURCE: Smulders M. ACC 18.

Pages

Recommended Reading

VEST: Closer tailoring might boost wearable cardioverter defibrillator’s benefit
MDedge Cardiology
ODYSSEY Outcomes trial redefines secondary cardiovascular prevention
MDedge Cardiology
Ticagrelor noninferior to clopidogrel in terms of major bleeds in STEMI
MDedge Cardiology
Wearable defibrillator cuts mortality in post-MI patients
MDedge Cardiology
OSA may provide cardioprotection
MDedge Cardiology
VIDEO: Patient vouchers prompt physicians to prescribe top antiplatelet drugs
MDedge Cardiology
Radial access PCI best for acute coronary syndrome patients
MDedge Cardiology
Febuxostat increases cardiovascular mortality in CARES trial
MDedge Cardiology
DOACs may be beneficial in post-op atrial fib after CABG
MDedge Cardiology
Drug coated balloons may match stents for small coronary lesions
MDedge Cardiology